Note 3 - Selected Balance Sheet Data (Tables)
|
6 Months Ended |
Dec. 31, 2021 |
|---|
| Notes Tables |
|
| Schedule of Inventory, Current [Table Text Block] |
| |
|
December 31, |
|
|
June 30, |
|
| |
|
2021 |
|
|
2021 |
|
| Raw materials |
|
$ |
61,624 |
|
|
$ |
55,096 |
|
| Finished goods(1) |
|
|
65,620 |
|
|
|
67,108 |
|
| Inventories, net |
|
$ |
127,244 |
|
|
$ |
122,204 |
|
|
| Property, Plant and Equipment [Table Text Block] |
| |
|
December 31, |
|
|
June 30, |
|
| |
|
2021 |
|
|
2021 |
|
| Land |
|
$ |
8,587 |
|
|
$ |
8,612 |
|
| Buildings and improvements |
|
|
225,501 |
|
|
|
190,661 |
|
| Machinery and equipment |
|
|
161,431 |
|
|
|
149,410 |
|
| Construction in progress |
|
|
17,386 |
|
|
|
49,073 |
|
| Property and equipment, cost |
|
|
412,905 |
|
|
|
397,756 |
|
| Accumulated depreciation and amortization |
|
|
(201,091 |
) |
|
|
(189,849 |
) |
| Property and equipment, net |
|
$ |
211,814 |
|
|
$ |
207,907 |
|
|
| Schedule of Intangible Assets and Goodwill [Table Text Block] |
| |
|
December 31, |
|
|
June 30, |
|
| |
|
2021 |
|
|
2021 |
|
| Developed technology |
|
$ |
544,388 |
|
|
$ |
552,160 |
|
| Trade names |
|
|
147,327 |
|
|
|
147,640 |
|
| Customer relationships |
|
|
228,419 |
|
|
|
232,493 |
|
| Patents |
|
|
3,116 |
|
|
|
2,926 |
|
| Other intangibles |
|
|
6,309 |
|
|
|
6,316 |
|
| Definite-lived intangible assets |
|
|
929,559 |
|
|
|
941,535 |
|
| Accumulated amortization |
|
|
(382,912 |
) |
|
|
(348,267 |
) |
| Definite-lived intangibles assets, net |
|
|
546,647 |
|
|
|
593,268 |
|
| In process research and development |
|
|
22,700 |
|
|
|
22,700 |
|
| Total intangible assets, net |
|
$ |
569,347 |
|
|
$ |
615,968 |
|
|
| Schedule of Finite-Lived Intangible Assets [Table Text Block] |
| Beginning balance |
|
$ |
615,968 |
|
| Acquisitions |
|
|
- |
|
| Other additions |
|
|
171 |
|
| Amortization expense |
|
|
(37,258 |
) |
| Currency translation |
|
|
(971 |
) |
| Eminence impairment (1)
|
|
|
(8,563 |
) |
| Ending balance |
|
$ |
569,347 |
|
|
| Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] |
| 2022 remainder |
|
$ |
36,927 |
|
| 2023 |
|
|
71,669 |
|
| 2024 |
|
|
68,818 |
|
| 2025 |
|
|
65,579 |
|
| 2026 |
|
|
61,819 |
|
| Thereafter |
|
|
241,835 |
|
| Total |
|
$ |
546,647 |
|
|
| Schedule of Goodwill [Table Text Block] |
| |
|
Protein Sciences |
|
|
Diagnostics and Genomics |
|
|
Total |
|
| Beginning balance |
|
$ |
392,717 |
|
|
$ |
450,350 |
|
|
$ |
843,067 |
|
| Acquisitions |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Eminence impairment |
|
|
(8,275 |
) |
|
|
- |
|
|
|
(8,275 |
) |
| Currency translation |
|
|
(2,610 |
) |
|
|
(126 |
) |
|
|
(2,736 |
) |
| Ending balance |
|
$ |
381,832 |
|
|
$ |
450,224 |
|
|
$ |
832,056 |
|
|